Jolkinolide B synergistically potentiates the antitumor activity of GPX4 inhibitors via inhibiting TrxR1 in cisplatin-resistant bladder cancer cells

• Published in: Biochemical pharmacology Vol. 223; p. 116194
• Main Authors: Sang, Jun, Liu, Chen-Kai, Liu, Jue, Luo, Guan-Cong, Zheng, Wei-Ji, Bai, Ya, Jiang, De-Yun, Pu, Jiang-Ni, An, Su, Xu, Tian-Rui
• Format: Journal Article
• Language: English
• Published: England Elsevier Inc 01.05.2024
• Subjects: Drug resistance; Jolkinolide B; Lipid peroxidation; Natural diterpenoid; Thioredoxin reductase 1; 4-PBA; Lipid peroxidation; GPX4i; MDA; DFO; MTT; Drug resistance; CHX; 4-HNE; shRNA; c-PARP; Jolkinolide B; BSO; c-cas-3; GPX4; siRNA; MAPK; TrxR1; ER; Thioredoxin reductase 1; NAC; CDDP; Natural diterpenoid; Lip-1; ROS; JB

[Display omitted] Glutathione peroxidase 4 (GPX4) is a promising anticancer therapeutic target; however, the application of GPX4 inhibitors (GPX4i) is limited owing to intrinsic or acquired drug resistance. Hence, understanding the mechanisms underlying drug resistance and discovering molecules that...